In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
It doesn't really matter where you think a stock should trade at.
Baxter buys generic drug maker Claris Injectables in a deal that will be accretive to earnings.
By acquiring Claris, Baxter expects to launch seven to nine new generic injectable medicines each year over the next several years.
Companies that marked turnarounds -- for better or worse -- last week.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.